• Lamees A Altamimi, Leen A Altamimi, and Ali M Somily.
• From the College of Medicine (Lamees Altamimi, Leen Altamimi), and from the Department of Pathology and Laboratory Medicine (Somily), King Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia.
• Saudi Med J. 2022 Jan 1; 43 (1): 31-36.

ObjectivesTo assess the antibacterial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa) from various body specimen types and different patterns of resistance.MethodsA retrospective cohort study with a total of 49 MRSA and 99 P. aeruginosa isolated in the Microbiology Laboratory at King Saud University Medical City, Riyadh, Saudi Arabia, between 2018-2019, were used. Isolates were randomly selected from various specimen types. The minimum inhibition concentration (MIC) of ceftobiprole was determined by E-test. Breakpoints carried out by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used to assess antibiotic susceptibility.ResultsApproximately 100% of the MRSA isolates were susceptible with MIC50/90 value of 1/1.5 mg/L while 69.8% of multi-drug resistant (MDR) P. aeruginosa isolates were resistant with MIC50/90 value of 16/32 mg/L.ConclusionThe excellent activity of ceftobiprole against MRSA would have major implications in management of the patients with serious infections, as an empirical treatment or alternative to vancomycin. Ceftobiprole has a very low activity against MDR P. aeruginosa, and its susceptibility should be tested prior to use for treatment.Copyright: © Saudi Medical Journal.

18 keywords...

hide…